These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18060862)

  • 1. CD200: a putative therapeutic target in cancer.
    Moreaux J; Veyrune JL; Reme T; De Vos J; Klein B
    Biochem Biophys Res Commun; 2008 Feb; 366(1):117-22. PubMed ID: 18060862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias.
    Wang W; Ji P; Steffen B; Metzger R; Schneider PM; Halfter H; Schrader M; Berdel WE; Serve H; Müller-Tidow C
    Acta Biochim Biophys Sin (Shanghai); 2005 Mar; 37(3):173-80. PubMed ID: 15756419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions.
    Koning N; Swaab DF; Hoek RM; Huitinga I
    J Neuropathol Exp Neurol; 2009 Feb; 68(2):159-67. PubMed ID: 19151626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligation of CD200R by CD200 is not required for normal murine myelopoiesis.
    Rijkers ES; de Ruiter T; Buitenhuis M; Veninga H; Hoek RM; Meyaard L
    Eur J Haematol; 2007 Nov; 79(5):410-6. PubMed ID: 17803680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of an expressed truncated form of CD200, CD200tr, which is a physiologic antagonist of CD200-induced suppression.
    Chen Z; Chen DX; Kai Y; Khatri I; Lamptey B; Gorczynski RM
    Transplantation; 2008 Oct; 86(8):1116-24. PubMed ID: 18946351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD200R signaling in tumor tolerance and inflammation: A tricky balance.
    Rygiel TP; Meyaard L
    Curr Opin Immunol; 2012 Apr; 24(2):233-8. PubMed ID: 22264927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD70 as a therapeutic target in human malignancies.
    Grewal IS
    Expert Opin Ther Targets; 2008 Mar; 12(3):341-51. PubMed ID: 18269343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia.
    Palumbo GA; Parrinello N; Fargione G; Cardillo K; Chiarenza A; Berretta S; Conticello C; Villari L; Di Raimondo F
    Leuk Res; 2009 Sep; 33(9):1212-6. PubMed ID: 19230971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Embryonic stem cell markers expression in cancers.
    Schoenhals M; Kassambara A; De Vos J; Hose D; Moreaux J; Klein B
    Biochem Biophys Res Commun; 2009 May; 383(2):157-62. PubMed ID: 19268426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STEAP1 is overexpressed in cancers: a promising therapeutic target.
    Moreaux J; Kassambara A; Hose D; Klein B
    Biochem Biophys Res Commun; 2012 Dec; 429(3-4):148-55. PubMed ID: 23142226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer.
    Cheng S; Liu W; Mercado M; Ezzat S; Asa SL
    Endocr Relat Cancer; 2009 Jun; 16(2):455-66. PubMed ID: 19261683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD200 is a new prognostic factor in multiple myeloma.
    Moreaux J; Hose D; Reme T; Jourdan E; Hundemer M; Legouffe E; Moine P; Bourin P; Moos M; Corre J; Möhler T; De Vos J; Rossi JF; Goldschmidt H; Klein B
    Blood; 2006 Dec; 108(13):4194-7. PubMed ID: 16946299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyaluronan-mediated motility: a target in oral squamous cell carcinoma.
    Yamano Y; Uzawa K; Shinozuka K; Fushimi K; Ishigami T; Nomura H; Ogawara K; Shiiba M; Yokoe H; Tanzawa H
    Int J Oncol; 2008 May; 32(5):1001-9. PubMed ID: 18425326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD200, a "no danger" signal for hair follicles.
    Rosenblum MD; Yancey KB; Olasz EB; Truitt RL
    J Dermatol Sci; 2006 Mar; 41(3):165-74. PubMed ID: 16386879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug transporters as targets for cancer chemotherapy.
    Nakanishi T
    Cancer Genomics Proteomics; 2007; 4(3):241-54. PubMed ID: 17878527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells.
    Huq A; Singh B; Meeker T; Mascarenhas D
    Anticancer Drugs; 2009 Jan; 20(1):21-31. PubMed ID: 19342998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD200 expression in patients with Multiple Myeloma: another piece of the puzzle.
    Conticello C; Giuffrida R; Parrinello N; Buccheri S; Adamo L; Sciuto MR; Colarossi C; Aiello E; Chiarenza A; Romano A; Salomone E; Gulisano M; Giustolisi R; Di Raimondo F
    Leuk Res; 2013 Dec; 37(12):1616-21. PubMed ID: 24183830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CD200 and CD200 receptor cell surface proteins interact through their N-terminal immunoglobulin-like domains.
    Hatherley D; Barclay AN
    Eur J Immunol; 2004 Jun; 34(6):1688-94. PubMed ID: 15162439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of a distal enhancer in the transcriptional responsiveness of the human CD200 gene to interferon-gamma and tumor necrosis factor-alpha.
    Chen Z; Marsden PA; Gorczynski RM
    Mol Immunol; 2009 Jun; 46(10):1951-63. PubMed ID: 19386363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD200 expression in plasma cell myeloma.
    Olteanu H; Harrington AM; Hari P; Kroft SH
    Br J Haematol; 2011 May; 153(3):408-11. PubMed ID: 21275968
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.